High-risk Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for High-risk Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating the combination of CPX-351 (liposomal cytarabine and daunorubicin) with Quizartinib for acute myelo…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital
This clinical trial update describes the creation of a biocollection of patients with acute myeloid leukemia, acute lymphoblastic leukemia, …
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Hu8F4 in Treating Patients With Advanced Hematologic Malignancies [Phase 1]
Hu8F4 is being studied in a Phase 1 trial for multiple advanced hematologic malignancies; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
A phase 1/2 clinical trial at MD Anderson is evaluating a quadruplet regimen of cladribine, idarubicin, cytarabine, and quizartinib for newl…
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: The Patient Cohort of the National Center for Precision Medicine in Leukemia
This clinical trial update describes the patient cohort for the National Center for Precision Medicine in Leukemia and notes that patient re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2014-06-11Clinical Trial Update: A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. [Phase 1, Phase 2]
This update notes the completion of a Phase 1/2 clinical trial evaluating the feasibility of combining three agents (Quizartinib, Plerixafor…